ABSTRACT: 

Type 2 diabetes mellitus (T2DM) is a global health issue that affect around 643 million people in 2030. Estimated prevalence of T2DM in adults aged 20–79 years has more than tripled, from an estimated 151 million (4.6% of the global population at the time) to 537 million (10.5%) today. This study analyze direct medical costs of insulin treatment with in T2DM outpatients. This retrospective descriptive economic evaluation was conducted in April 2023 on the basis of payer (called as Badan Penyelenggara Jaminan Sosial abbreviated as BPJS) perspective, then only direct costs were included in this study. Component of direct medical cost of this research include drug acquisition costs, physician service, laboratory examination, medical execution and administration. 58 T2DM outpatients met inclusion criteria in Universitas Sumatera Utara was recruited by simple random sampling. Result of this study show that most of respondent were aged 56-65 years (58.89%). Cost/year/patient of drug acquisition costs was Rp.4,7228,970.14; physician service was Rp.1,865,172.41; laboratory examination was Rp.443,379.31; and medical execution was Rp.31,030.48 and administration was Rp.300,000.00, respectively. Drug acquisition costs was the largest cost in treating T2DM patients with insulin treatment.

KEYWORDS :

Direct medical costs, insulin treatment, T2DM, outpatients

REFERENCES :

1) Arvita, G. (2024). APPLICATION OF FOOT EXERCISES ON FEET SENSITIVITY AND BLOOD SUGAR LEVELS IN TYPE II DIABETES MELLITUS PATIENTS . Berdasarkan Laporan Nasional Riskesdas. 4, 238–245.
2) Byberg, S., Bundesen, C., Rudolf, F., Haraldsdottir, T. L., Indjai, L., Barai, R., Beck-Nielsen, H., Sodemann, M., Jensen, D. M., & Bjerregaard-Andersen, M. (2020). Diabetes in urban Guinea-Bissau; patient characteristics, mortality and prevalence of undiagnosed dysglycemia. Global Health Action, 13(1).

https://doi.org/10.1080/16549716.2020.1802136

3) Chawla, R., Madhu, S., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020). RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism, 24(1), 1–122. https://doi.org/10.4103/ijem.IJEM_225_20
4) Ciarambino, T., Crispino, P., Leto, G., Mastrolorenzo, E., Para, O., & Giordano, M. (2022). Influence of Gender in Diabetes Mellitus and Its Complication. International Journal of Molecular Sciences, 23(16), 1–13. https://doi.org/10.3390/ijms23168850
5) Doyle, G. A., O’Donnell, S., Cullen, K., Quigley, E., & Gibney, S. (2022). Understanding the cost of care of type 2 diabetes mellitus – A value measurement perspective. BMJ Open, 12(1). https://doi.org/10.1136/bmjopen-2021-053001
6) Erzse, A., Stacey, N., Chola, L., Tugendhaft, A., Freeman, M., & Hofman, K. (2019). The direct medical cost of type 2 diabetes mellitus in South Africa: a cost of illness study. Global Health Action, 12(1). https://doi.org/10.1080/16549716.2019.1636611
7) Fitria, N., Fitri Anggraini, L., & Oktavia Sari, Y. (2023). Cost-Effectiveness Analysis of the Combination of Metformin-Insulin Glargine and Metformin-Glimepiride in Type 2 Diabetes Mellitus Patients in Rupit Hospital. Journal of Health Economic and Policy Research (JHEPR), 1(1), 18–23. https://doi.org/10.30595/jhepr.v1i1.65
8) Gupta, N., Verma, R., Dhiman, R. K., Rajsekhar, K., & Prinja, S. (2020). Cost-Effectiveness Analysis and Decision Modelling: A Tutorial for Clinicians. Journal of Clinical and Experimental Hepatology, 10(2), 177–184.

https://doi.org/10.1016/j.jceh.2019.11.001
9) Haahr, H., & Heise, T. (2020). Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clinical Pharmacokinetics, 59(2), 155–172.

https://doi.org/10.1007/s40262-019-00834-5
10) Hidayat, B., Ramadani, R. V., Rudijanto, A., Soewondo, P., Suastika, K., & Siu Ng, J. Y. (2022). Direct Medical Cost of Type 2 Diabetes Mellitus and Its Associated Complications in Indonesia. Value in Health Regional Issues, 28, 82–89. https://doi.org/10.1016/j.vhri.2021.04.006
11) Larasanty, L. P. F., Sarasmita, M. A., & Dewantara Putra, I. G. N. A. (2018). Cost-effectiveness analysis of insulin regimen on type 2 diabetes mellitus outpatient in denpasar municipality. Asian Journal of Pharmaceutical and Clinical Research, 11(1), 89–92. https://doi.org/10.22159/ajpcr.2018.v11i1.18695
12) Nanayakkara, N., Curtis, A. J., Heritier, S., Gadowski, A. M., Pavkov, M. E., Kenealy, T., Owens, D. R., Thomas, R. L., Song, S., Wong, J., Chan, J. C. N., Luk, A. O. Y., Penno, G., Ji, L., Mohan, V., Amutha, A., Romero-Aroca, P., Gasevic, D., Magliano, D. J., … Zoungas, S. (2021). Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia, 64(2), 275–287. https://doi.org/10.1007/s00125-020-05319-w
13) Nedyalkova, M., Madurga, S., Ballabio, D., Robeva, R., Romanova, J., Kichev, I., Elenkova, A., & Simeonov, V. (2020). Diabetes mellitus type 2: Exploratory data analysis based on clinical reading. Open Chemistry, 18(1), 1041–1053.

https://doi.org/10.1515/chem-2020-0086
14) Novita, A., Marniati, M., Husna, A., Iskandar, I., Putranto, R. H., Putri, E. S., & Anwar, S. (2022). Study of Intrinsic and Extrinsic Factors with Diabetes Mellitus Classification. J-Kesmas: Jurnal Fakultas Kesehatan Masyarakat (The Indonesian Journal of Public Health), 9(2), 18. https://doi.org/10.35308/j-kesmas.v9i2.5982
15) Triyaniarta, A. R., Martini, S., Artanti, K. D., Widati, S., & Nastiti, R. D. (2022). Determinants of Type 2 Diabetes Mellitus among Passive Smokers. Kesmas, 17(3), 191–197. https://doi.org/10.21109/kesmas.v17i3.5723
16) Tseng, H. H. K., Nkimbeng, M., & Han, H. R. (2022). Gender differences in psychosocial characteristics and diabetes self-management among inner-city African Americans. Nursing Open, 9(5), 2425–2433.
https://doi.org/10.1002/nop2.1259
17) Udayani, N. N. W., & Adnyani, P. M. D. (2022). Analisis Efektivitas Biaya Penggunaan Terapi Insulin Kombinasi dan Insulin Tunggal pada Pasien Diabetes Melitus tipe 2. Cerdika: Jurnal Ilmiah Indonesia, 2(1), 108–116.

https://doi.org/10.36418/cerdika.v2i1.322
18) Udayani, N. N. W., Ratnasari, N. L. A. M., Cahyaningsih, E., & Wardani, I. G. A. A. K. (2021). Evaluasi Efek Samping Penggunaan Kombinasi Insulin pada Pasien Diabetes Melitus Tipe 2 di Salah Satu Rumah Sakit Kabupaten Denpasar. Jurnal Ilmiah Medicamento, 7(2), 112–117. https://doi.org/10.36733/medicamento.v7i2.2178
19) Wang, Y., Zhou, Y., Ding, J., Li, X., Guo, F., Zhang, J., & Ding, L. (2022). Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints. Frontiers in Pharmacology, 13(August), 1–10. https://doi.org/10.3389/fphar.2022.962201